aTyr Pharma, Inc. (NASDAQ:LIFE) Weekly Ratings on Apr 16, 2018

April 16, 2018 - By Anthony Rauscher

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

In total 3 analysts cover aTyr Pharma (NASDAQ:LIFE). “Buy” rating has 0, “Sell” are 2, while 1 are “Hold”. 0 are bullish. 4 are the (NASDAQ:LIFE)’s analyst reports since November 1, 2017 according to StockzIntelligence Inc. In Wednesday, November 1 report BMO Capital Markets maintained it with “Hold” rating and $4.0 target. On Wednesday, February 14 the stock has “Sell” rating by J.P. Morgan. On Wednesday, February 14 the stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Underweight” rating by JP Morgan. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
14/11/2017 Broker: J.P. Morgan Rating: Hold
01/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $4.0 Maintain

LIFE reached $2.75 on during the last trading session after $0.15 change.Currently aTyr Pharma, Inc. is downtrending after 19.01% change in last April 16, 2017. LIFE has 12,099 shares volume. LIFE underperformed the S&P500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is worth $81.94 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Last it reported negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: